CE Discussion Group’s Post

Simon Christian Vinther will be defending his PhD thesis with a talk entitled "Guiding the delivery of nucleic acid-based therapeutics with carbohydrate modifications" on Wednesday 15 May 2024 at Aarhus University During his PhD studies, Simon Christian Vinther investigated the use of carbohydrate-guided therapeutics to target specific cells or organs, in the interest of improving drug delivery of nucleic acid-based drugs. Nucleic acids are remarkable for creating unique structures that can be chemically modified with e.g. carbohydrates at precise placements. By utilizing these properties, Simon Christian Vinther created carbohydrate-modified nucleic acid-based therapeutics, designed with different sugar patterns. The carbohydrate-modified therapeutics can bind specific subsets of sugar-recognizing receptors called C-type lectins, enabling the nucleic acid-based drugs to be taken up by the targeted cells. Simon Christian Vinther applied these carbohydrate-modified nucleic acid therapeutics to study the drug delivery to hepatocytes or immune cells. His research findings contribute to advancing drug delivery of future nucleic acid-based therapeutics. Members of the assessment committee: Professor Christoph Rademacher, Department of Pharmaceutical Sciences, University of Vienna, Austria Professor Hanne Mørck Nielsen, Department of Pharmacy, Copenhagen University, Denmark Professor Mingdong Dong, Interdisciplinary Nanoscience Center (iNANO), Aarhus University (chair) Main supervisor: Professor Jørgen Kjems, iNANO/MBG, Aarhus University, Denmark Co-supervisor: Assistant Professor Julián Valero Moreno, iNANO/MBG, Aarhus University, Denmark Interdisciplinary Nanoscience Center - Aarhus University Faculty of Natural Sciences - Aarhus University Aarhus University #nucleicacidbasedtherapeutics #nucleicacids #carbohydratemodification #carbohydrateguidedtherapeutics #drugdelivery #carbohydrates #molecularbiology #Ctypelectins #hepatocytes #immunecells #cellbiology #phddefence #university

The European Pharma Days are approaching. Commit a little of your time and join us in Mannheim on April 23rd and 24th. Listen to great scientific presentations and discuss with our speakers about #Immunopeptidomics, #TPD, #Imaging and #Biologics Characterization. Have a look on the detailed agenda on the #Bruker website and register for this free of charge event: https://lnkd.in/e4WZ6uXe   #TIMS #diaPASEF #Proteomics #Metabolomics #spatialbiology

🌟 Exciting News from molE@PoliTO 🌟 We are pleased to announce the publication of our latest research, conducted in collaboration with Fresenius Kabi, Redshiftbio, and Politecnico di Torino (molE Group). This study explores the challenging problem of peptide aggregation in biopharmaceutical development and neurodegenerative diseases. Our research combines computational simulations and experimental validation to uncover the aggregation mechanisms of glucagon, a peptide with a high tendency to aggregate. Key findings reveal that lactose and 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) have distinct effects on glucagon: 🧬 Lactose stabilizes glucagon by increasing its α-helical content. 🧪 2-HPβCD disrupts protein-protein interactions, effectively preserving the monomeric form of glucagon. Using microfluidic modulation spectroscopy (MMS), we confirmed that 2-HPβCD maintains the structural stability of glucagon, supporting its anti-aggregation properties. This research not only provides crucial insights into glucagon aggregation but also introduces a powerful tool for monitoring peptide aggregation, paving the way for innovative strategies in therapeutic peptide development. Read the full study here: https://lnkd.in/dxAd64D3 #Peptide #Protein #MolecularDynamics #Biopharmaceuticals #NeurodegenerativeDiseases #ProteinAggregation #ScientificResearch #Mole #PolitecnicoDiTorino

A Call for 2025 OTS Lifetime Achievement Award Nominations 📢 Would you like to help bestow the prestigious OTS Lifetime Achievement Award upon a leader in the field of oligonucleotide therapeutics? Every year, the OTS requests nominations for those who have steadfastly advanced the field of oligonucleotide therapeutics through their lasting dedication and outstanding contributions. Who are the standouts in your environment, who have published numerous scientific contributions, mentored the upcoming generation, or provided leadership in academia or the industry? These stellar individuals need not be OTS members to be a nominee, nor do you as a nominator. Eligible nominees can come from anywhere in the industry or academic world, including those holding emeritus status. It's easy to nominate someone for this award, simply fill out a short online form and submit a letter detailing the nominee's accomplishments and why this person exemplifies the essence of the award. To honor the recipient of this award, a financial reward and other gifts will be given at the 2025 OTS Annual Meeting, during a formal presentation. Winning the OTS Lifetime Achievement Award gives the recipient a keynote speaking slot at the annual meeting to share their insights and inspire others. Deadline for nominations: June 1, 2024 Read the guidelines and submit your nomination here: https://lnkd.in/gAzDm78 #OTSLifetimeAchievement #OTS #oligotherapeutics #oligonucleotides #biotech #biotechnology #science #research #biology #microbiology #medical #cellbiology #biotechnologystudent #chemistry #pharmaceuticals #scientificcommunity

#ScienceFridays 🔬 Research paper of the week ➡ ‘Multi-Omics Analysis Identified Drug Repurposing Targets for Chronic Obstructive Pulmonary Disease’ 🔎 Abstract: Despite recent advances in chronic obstructive pulmonary disease (COPD) research, few studies have identified the potential therapeutic targets systematically by integrating multiple-omics datasets. This project aimed to develop a systems biology pipeline to identify biologically relevant genes and potential therapeutic targets that could be exploited to discover novel COPD treatments via drug repurposing or de novo drug discovery. ✍️ Authors: Fang Wang and Carlos Barrero. 🏫 Affiliation: Department of Pharmaceutical Sciences at Temple University School of Pharmacy. 📄 Published on: International Journal of Molecular Sciences (MDPI) Find the link to the article on our #DrugRepurposing Research Collection, curated via ScienceOpen 🔗 https://lnkd.in/eFnAhXxV #FutureOfMedicine #OpenScience #Bioinformatics #Biomedicine #DrugDiscovery #PulmonaryDisease

🎉 Our latest paper "Stereorandomized Oncocins with Preserved Ribosome Binding and Antibacterial Activity" by Bee Ha Gan, Etienne Bonvin, Thierry Paschoud, Hippolyte Personne, PhD, Jérémie Reusser, Xingguang Geo Cai, Robert Rauscher, Thilo Köhler, Christian van Delden, Norbert Polacek, and Jean-Louis Reymond is now published on ACS Division of Medicinal Chemistry! In this study, we tested whether stereorandomization, which can modulate the activity, toxicity, and stability of membrane-disruptive antimicrobial peptides (AMPs), could be compatible with target-binding peptides. Our experiments show that stereorandomization of up to nine C-terminal residues of the proline-rich AMP oncocin preserved both antibacterial effects and ribosome binding. These findings can help in understanding the mechanisms of action of such target-binding peptides. Read the full version here 👉https://lnkd.in/e5vRzmfV Abstract We recently showed that solid-phase peptide synthesis using racemic amino acids yields stereorandomized peptides comprising all possible diastereomers as homogeneous, single-mass products that can be purified by HPLC and that stereorandomization modulates activity, toxicity, and stability of membrane-disruptive cyclic and linear antimicrobial peptides (AMPs) and dendrimers. Here, we tested if stereorandomization might be compatible with target binding peptides with the example of the proline-rich AMP oncocin, which inhibits the bacterial ribosome. Stereorandomization of up to nine C-terminal residues preserved ribosome binding and antibacterial effects including activities against drug-resistant bacteria and protected against serum degradation. Surprisingly, fully stereorandomized oncocin was as active as L-oncocin in dilute growth media stimulating peptide uptake, although it did not bind the ribosome, indicative of an alternative mechanism of action. These experiments show that stereorandomization can be compatible with target binding peptides and can help understand their mechanism of action. DCBP - Department of Chemistry, Biochemistry and Pharmaceutical Sciences (University of Bern) University of Bern Reymond Group

In a new study we introduce an AI-assisted drug discovery approach and use it to generate over 14.9 million novel peptides with appealing pharmaceutical features, including molecules that inhibit key proteins linked to coronavirus infection and cancer in the lab. This research was led by Patrick Salveson, Ph.D., a recent postdoc in the Baker Lab. It led to a spinout company, Vilya, which emerged from the Institute for Protein Design in 2022. The molecules developed in the study, which are ring-shaped peptides called macrocycles, have the potential to treat a wide range of health disorders. The number and diversity of macrocycles described in this study far exceed what has been found in nature, and roughly half satisfy the so-called ‘rule-of-five’ criteria for drug-like compounds. Read a summary and access the full paper on the Baker Lab blog: https://lnkd.in/gX5xNkpq

Could this be done with peptodmimetics?

RNA - technology of the future in life sciences. Global RNA therapeutics market size was valued at USD 23,067.85 million in 2023, expected to reach USD 54,464.95 million in 2031. Factors impacting the global RNA therapeutics market include progress in RNA technology, augmented research funding, heightened incidence of chronic diseases, demand for personalized medicine, the effectiveness of RNA-based drugs in treating previously incurable conditions, and the substantial influence of regulatory support and collaborations among pharmaceutical firms contributing to market expansion. Read: https://lnkd.in/gxXm5hVm #sciencesdelavie #biotechnology #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #revolution #happy

Just one of our newest advancements! NeuroKey-3 is a pre-validated panel that simultaneously measures extremely low-level, clinically relevant biomarkers for neurodegenerative diseases. Attend our webinar on May 16th to learn how it can benefit clinical programs. #NeurodegenerativeDiseases #Biomarkers #ClinicalResearch